We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
-5.01%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$7.91B
AUM Growth
-$1.41B
(-15%)
Cap. Flow
-$1B
Cap. Flow
% of AUM
-12.68%
Top 10 Holdings %
Top 10 Hldgs %
40.65%
Holding
174
New
35
Increased
19
Reduced
37
Closed
35
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LABP
Landos Biopharma, Inc. Common Stock
LABP
|
+$194M |
| 2 |
BridgeBio Pharma
BBIO
|
+$68.7M |
| 3 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$68.4M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$62.1M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$52.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novavax
NVAX
|
+$116M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$100M |
| 3 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
+$90.4M |
| 4 |
NVTA
Invitae Corporation
NVTA
|
+$87.4M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$87.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.08% |
| 2 | Financials | 0.47% |
| 3 | Industrials | 0.2% |
| 4 | Consumer Discretionary | 0.02% |
| 5 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $595M | 7.53% |
3,474,505
-219,011
| -6% | -$43.4M |
|
|
2
BridgeBio Pharma
BBIO
$16.5B
| $478M | 6.04% |
7,756,928
+1,050,660
| +16% | +$68.7M |
|
|
SWTX
3
DELISTED
SpringWorks Therapeutics
SWTX
| $357M | 4.51% |
4,849,912
+672,191
| +16% | +$52.6M |
|
4
Iovance Biotherapeutics
IOVA
$2.02B
| $274M | 3.46% |
8,651,785
-514,519
| -6% | -$21.3M |
|
|
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
| $226M | 2.86% |
22,861,329
-2,250,719
| -9% | -$34.8M |
|
6
CALL
Biogen
BIIB
$31.4B
| $209M | 2.65% |
+748,000
| New | +$202M |
|
|
GBT
7
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $206M | 2.61% |
5,058,642
-616,069
| -11% | -$28.3M |
|
|
NVTA
8
DELISTED
Invitae Corporation
NVTA
| $205M | 2.59% |
5,360,673
-1,923,793
| -26% | -$87.4M |
|
|
HZNP
9
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $189M | 2.39% |
2,050,002
-1,034,040
| -34% | -$87.3M |
|
10
Atea Pharmaceuticals
AVIR
$360M
| $185M | 2.34% |
3,109,224
| – | – |
|
|
VBIV
11
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $171M | 2.16% |
1,834,749
| – | – |
|
|
12
PUT
Biogen
BIIB
$31.4B
| $168M | 2.12% |
+600,000
| New | +$162M |
|
|
LABP
13
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
| $141M | 1.78% |
+1,486,992
| New | +$194M |
|
14
Zymeworks
ZYME
$1.62B
| $137M | 1.73% |
4,330,868
+29,869
| +0.7% | +$1.21M |
|
15
Outset Medical
OM
$86.8M
| $130M | 1.64% |
159,169
-30,686
| -16% | -$23.7M |
|
16
Rocket Pharmaceuticals
RCKT
$333M
| $127M | 1.61% |
2,867,771
-529,096
| -16% | -$29.1M |
|
17
C4 Therapeutics
CCCC
$388M
| $117M | 1.48% |
3,158,566
| – | – |
|
|
NVRO
18
DELISTED
NEVRO CORP.
NVRO
| $113M | 1.43% |
812,154
-165,411
| -17% | -$27M |
|
19
Aldeyra Therapeutics
ALDX
$95.3M
| $103M | 1.31% |
8,703,879
+2,418,421
| +38% | +$27.8M |
|
20
MeiraGTx Holdings
MGTX
$1.07B
| $93.4M | 1.18% |
6,933,277
| – | – |
|
|
21
Neurocrine Biosciences
NBIX
$18.2B
| $91.6M | 1.16% |
941,832
-957,383
| -50% | -$100M |
|
|
ALBO
22
DELISTED
Albireo Pharma Inc
ALBO
| $83.2M | 1.05% |
2,360,139
| – | – |
|
23
Travere Therapeutics
TVTX
$5.13B
| $82.4M | 1.04% |
3,298,419
-195,188
| -6% | -$5.39M |
|
|
KRON
24
DELISTED
Kronos Bio
KRON
| $79.7M | 1.01% |
2,780,097
| – | – |
|
25
Solid Biosciences
SLDB
$789M
| $74.2M | 0.94% |
894,170
+173,913
| +24% | +$19.2M |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q1 2021 Portfolio in Review
As of Q1 2021, Perceptive Advisors held 174 positions worth $7.91B, down 15% from $9.32B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Perceptive Advisors withdrew a net $1B in Q1 2021, closing 35 positions and reducing 37 holdings. Its most notable exit was Novavax, an estimated $116M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.
Against the trend, Perceptive Advisors opened a new position in Landos Biopharma, Inc. Common Stock worth $141M.
- Perceptive Advisors's largest Q1 2021 buy was Landos Biopharma, Inc. Common Stock: 1,486,992 shares worth $141M.
- Perceptive Advisors added most to BridgeBio Pharma in Q1 2021, an estimated $68.7M increase.
- Perceptive Advisors's biggest Q1 2021 reduction was Neurocrine Biosciences, cutting an estimated $100M.
- Perceptive Advisors fully exited Novavax in Q1 2021, selling an estimated $116M.
- Perceptive Advisors's ten largest holdings make up 41% of its $7.91B portfolio in Q1 2021.
- Perceptive Advisors opened 35 new positions and closed 35 in Q1 2021.
- Perceptive Advisors's portfolio value fell 15% quarter-over-quarter to $7.91B.
Based on Perceptive Advisors's 13F filing for Q1 2021, filed 17 May 2021.